Annual Information Form for the year ended December 31, 2024, which may be accessed on Vertex's SEDAR+ profile at www.sedarplus.ca. The forward-looking statements contained in this Press Release ...

What is happening today in Washington is a travesty. And the only ones who can prevent it from going further are the people ...

derives from Vertex’ near $1 billion acquisition of Semma in 2019, and has started enrolling patients in a phase 1/2 study in the US. The therapy takes the form of stem cell-derived human ...

Vertex' therapy takes the form of stem cell-derived human pancreatic islet cells, which secrete insulin in the body in response to rising blood glucose. The aim is to replace the pancreatic tissue ...

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

Nonprofit organizations utilizing the latest ezCheckprinting and virtual printer software no longer need be concerned about ...

If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Walmart's week-long sale has plenty of deals—these are worth your moneyBy Consumer ReportsIf you’ve been waiting for a big ...

AI is impacting all industries but none more than the publishing business model which lives or dies based on the content it ...

Morgan Stanley raised the firm’s price target on Vertex (VERX) to $60 from $57 and keeps an Overweight rating on the shares. The company’s ...

Vertex Pharmaceuticals has a 1 year low of $377.85 and a 1 year high of $519.88. The stock’s 50 day simple moving average is $464.06 and its 200-day simple moving average is $462.31.